In 2025, the United States healthcare system finds itself at a critical turning point. On one hand, the FDA’s approval of new obesity drugs represents a landmark in tackling the obesity epidemic. On the other, persistent Ivermectin myths—rooted in pandemic-era misinformation—continue to undermine public trust in science-based medicine. The tension...